TOP STORIES
respiratory
COPD

PBS broadens access to COPD triple therapy and lung cancer immunotherapy


For COPD patients the PBS is to remove the clinical criteria restricting access to patients with a FEV1 <50% of predicted for triple therapy Trelegy (fluticasone furoate with umeclidinium and vilanterol) from 1 March 2020. The move is expected to allow...

For COPD patients the PBS is to remove the clinical criteria restricting access to patients with a FEV1 <50% of...

Read more